Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1546-1553

  Haber, Michelle ^a   Smith, Janice ^a   Bordow, Sharon B ^a   Flemming, Claudia ^a   Cohn, Susan L ^a   London, Wendy B ^a   Marshall, Glenn M ^a   Norris, Murray D ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM; PROTEIN TYROSINE KINASE A; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ARTICLE; CANCER STAGING; CANCER SURGERY; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEWBORN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADOLESCENT; DRUG RESISTANCE; GENE; GENE AMPLIFICATION; GENETICS; MORTALITY; MULTIVARIATE ANALYSIS; ONCOGENE; PRESCHOOL CHILD; PROSPECTIVE STUDY; WESTERN BLOTTING;

ADOLESCENT; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENES, MDR; HUMANS; INFANT; INFANT, NEWBORN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENES; PROSPECTIVE STUDIES;

EID: 33645747683     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.6196     Document Type: Article

References (36)

1. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216, 2003
2. Brodeur GM, Castleberry RP: Neuroblastoma, in Pizzo PA, Poplack DG (eds): Principles and Practices of Pediatric Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 761-791
3. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid disease progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
4. Bown N: Neuroblastoma tumour genetics: Clinical and biological aspects. J Clin Pathol 54:897-910, 2001
5. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58, 2002
6. Bader P, Schilling F, Schlaud M, et al: Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep 6:1143-1146, 1999
7. Bordow S, Haber M, Madafiglio J, et al: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54:5036-5040, 1994
8. Goto H, Keshelava N, Matthay KK, et al: Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med Pediatr Oncol 35:619-622, 2000
9. Norris M, Bordow S, Marshall G, et al: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231-238, 1996
10. Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma. Am J Pathol 142:1339-1346, 1993
11. Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984
12. Alvarado CS, London WB, Look AT, et al: Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 22:197-205, 2000
13. Bowman LC, Castleberry RP, Cantor A, et al: Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study. J Natl Cancer Inst 89:373-380, 1997
14. Strother D, van Hoff J, Rao PV, et al: Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: Results from the Pediatric Oncology Group. Eur J Cancer 33:2121-2125, 1997
15. Katzenstein HM, Bowman LC, Brodeur GM, et al: Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience - A Pediatric Oncology Group study. J Clin Oncol 16:2007-2017, 1998
16. Burkhart CA, Cheng AJ, Madafiglio J, et al: Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95:1394-1403, 2003
17. Winer J, Jung CKS, Shackel I, et al: Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41-49, 1999
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
20. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
21. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005
22. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993
23. Schwab M: MYCN in neuronal tumours. Cancer Lett 204:179-187, 2004
24. Haber M, Bordow S, Gilbert J, et al: Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 18:2777-2782, 1999
25. Norris M, Bordow S, Haber P, et al: Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur J Cancer 33:1911-1916, 1997
26. Manohar CF, Bray JA, Salwen HR, et al: MYCN mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23:753-762, 2004
27. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999
28. Homolya L, Varadi A, Sarkadi B: Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 17:103-114, 2003
29. Renes J, de Vries EE, Hooiveld GJ, et al: Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J 350:555-561, 2000
30. Borst P, Evers R, Kool M, et al: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302, 2000
31. Kruh GD, Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22:7537-7552, 2003
32. Kigawa J, Minagawa Y, Cheng X, et al: Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 4:1737-1741, 1998
33. Kuo MT, Bao JJ, Curley SA, et al: Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 56:3642-3644, 1996
34. Ishikawa T, Bao JJ, Yamane Y, et al: Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271:14981-14988, 1996
35. Lu QJ, Dong F, Zhang JH, et al: Expression of multidrug resistance-related markers in primary neuroblastoma. Chin Med J 117:1358-1363, 2004
36. Allen JD, Brinkhuis RF, van Deemter L, et al: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60:5761-5766, 2000